EUVIMEDEUVIMED entdecken
Open Access

LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors

Ziyi He, Wei Feng, Yuxuan Wang, Liang Shi, Yuhui Gong, Yichao Shi, Shiyu Shen, Haitao Huang

Translational Lung Cancer Research · 2023-03 · 12 (3) · 510-529

DOI: 10.21037/tlcr-23-39 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Lung Cancer Research, 2023-03. Verfasst von Ziyi He und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China. Die Arbeit wurde bisher 29-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

LPR1BLung adenocarcinoma (LUAD)biomarkerimmune checkpoint inhibitors (ICIs)tumor immune microenvironment (TIME)

Autor:innen und Institutionen

  • Department of Thoracic Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.

Zitieren

APA

He, Z., Feng, W., Wang, Y., Shi, L., Gong, Y., Shi, Y., Shen, S., & Huang, H. (2023). LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors. Translational Lung Cancer Research, 12(3), 510-529. https://doi.org/10.21037/tlcr-23-39

Vancouver

He Z, Feng W, Wang Y, Shi L, Gong Y, Shi Y, et al. LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors. Translational Lung Cancer Research. 2023;12(3):510-529. doi:10.21037/tlcr-23-39

BibTeX
@article{He2023,
  author = {He, Ziyi and Feng, Wei and Wang, Yuxuan and Shi, Liang and Gong, Yuhui and Shi, Yichao and Shen, Shiyu and Huang, Haitao},
  title = {LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors},
  journal = {Translational Lung Cancer Research},
  year = {2023},
  volume = {12},
  number = {3},
  pages = {510--529},
  doi = {10.21037/tlcr-23-39}
}
Kostenlos starten →